Press release

11 Jun 2025 – OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for the Global Markets

10 Jun 2025 – OneSource’s flagship drug-device combinations facility in Bangalore maintains its USFDA compliance status

05 May 2025 – OneSource Reports Strong Q4 and FY25 Results – Q4FY25 Revenues of ₹4,260 million with an EBTDA of ₹1,825 million, demonstrating EBITDA margin of 43%

10 Apr 2025 – OneSource Secures approval from Brazil for its flagship facility

28 Feb 2025 – OneSource strengthens its Board by appointing three new Independent Directors

29 Jan 2025 – OneSource announces strong financial results in its first quarter post listing; Q3FY25 revenues at ₹3,926 million with an EBITDA of ₹1,432 million, demonstrating a 36.5% EBITDA margin

28 Jan 2025 – OneSource receives EIR with ‘Voluntary Action Indicated’ classification from USFDA for its BLD Facility

16 Oct 2024 – Press Release w.r.t Equity Commitments received by the Company from marquee Investors

08 Oct 2024 – Intimation of press release w.r.t launching of a new brand identity at CPHI, Milan

30 Jul 2024 – OneSource and Bhami’s Research Laboratory entered into Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously

OneSource and Bhami’s Research Laboratory entered into Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously